ZNF471

ZNF471 is a KRAB-domain zinc finger transcriptional regulator that functions as a tumor suppressor by directly binding gene promoters to either repress or activate transcription in a context-dependent manner. It recruits the co-repressor KAP1/TRIM28 to the promoters of oncogenes such as TFAP2A, PLS3, and c-Myc, inducing H3K9me3-mediated heterochromatization and transcriptional silencing (PMID:29610526, PMID:38749608), while at other loci it activates expression, as demonstrated by direct binding to and upregulation of the MAPK10/JNK3 promoter (PMID:32089740). ZNF471 suppresses multiple oncogenic signaling cascades—including AKT, Wnt/β-catenin, and PI3K/AKT/mTOR—through mechanisms that include physical interaction with BANP (PMID:33203470, PMID:38169650). Its nuclear function is regulated post-translationally by N-glycosylation at Asn358, which reduces protein stability and impairs nuclear translocation, thereby attenuating its transcriptional repression of c-Myc (PMID:38749608).

1. 2018 High

   Establishing that ZNF471 is a direct transcriptional repressor that silences specific oncogene promoters via KAP1 recruitment and H3K9me3 deposition answered the fundamental question of how this KRAB-ZFP exerts tumor-suppressive function at the chromatin level.

   Evidence ChIP-PCR showing ZNF471 binding to TFAP2A and PLS3 promoters with KAP1 co-occupancy and H3K9me3 enrichment in gastric cancer cells

   PMID:29610526

   Open questions at the time

   • Genome-wide binding profile not determined; additional target promoters likely exist
   • Whether ZNF471-KAP1 complex recruits SETDB1 or another H3K9 methyltransferase not tested
   • Mechanism distinguishing repressed versus activated targets unknown
2. 2020 High

   Demonstrating that ZNF471 can also activate transcription—by directly binding and upregulating the MAPK10/JNK3 promoter—revealed dual transcriptional activity beyond simple KRAB-mediated repression.

   Evidence ChIP assay and ectopic expression in esophageal squamous cell carcinoma cells with in vivo validation

   PMID:32089740

   Open questions at the time

   • Cofactors enabling transcriptional activation at MAPK10 versus repression at TFAP2A not identified
   • Whether PCDH family genes are direct or indirect targets not resolved by ChIP
3. 2020 Medium

   Showing that ZNF471 suppresses AKT and Wnt/β-catenin signaling in breast cancer extended its tumor-suppressive role beyond direct promoter targets to broader signaling pathway modulation, while the identification of ZNF471 as a downstream effector of the LIFR-AS1/miR-942-5p ceRNA axis in NSCLC established an upstream regulatory mechanism.

   Evidence Ectopic expression and knockdown with pathway readouts in breast cancer; luciferase reporter and rescue experiments in NSCLC

   PMID:32489316 PMID:33203470

   Open questions at the time

   • Direct binding to AKT or Wnt pathway gene promoters not demonstrated
   • Whether miR-942-5p regulation of ZNF471 operates across cancer types not tested
   • Endogenous stoichiometry of ceRNA sponge mechanism not validated
4. 2024 Medium

   Identifying BANP as a physical interaction partner of ZNF471 that cooperates to inactivate PI3K/AKT/mTOR signaling provided the first non-KAP1 protein partner and a candidate mechanism for pathway suppression in renal cell carcinoma.

   Evidence Co-immunoprecipitation of ZNF471-BANP complex, transcriptome sequencing, and functional assays in renal cell carcinoma

   PMID:38169650

   Open questions at the time

   • Reciprocal Co-IP and domain mapping of the ZNF471-BANP interface not reported
   • Whether BANP interaction is direct or bridged by other factors not resolved
   • Mechanism by which ZNF471-BANP complex inhibits PI3K/AKT/mTOR not defined
5. 2024 High

   Demonstrating that N-glycosylation at Asn358 destabilizes ZNF471 and blocks its nuclear translocation revealed a post-translational switch controlling ZNF471 function, linking glycosylation status to c-Myc repression.

   Evidence Site-directed mutagenesis of N358, ChIP for c-Myc promoter binding, and protein stability/localization assays in tongue squamous cell carcinoma

   PMID:38749608

   Open questions at the time

   • The glycosyltransferase responsible for Asn358 modification not identified
   • Whether N-glycosylation regulation applies to other ZNF471 target genes not tested
   • Structural basis for how glycosylation affects nuclear import unclear

• The genome-wide direct target repertoire of ZNF471, the structural basis for its dual activator/repressor function, and the identity of the glycosyltransferase modifying Asn358 remain unresolved.
• No ChIP-seq or CUT&RUN data available for genome-wide binding
• Structural determinants of context-dependent activation versus repression unknown
• In vivo genetic models (knockout mice) not reported